Skip to main content

Appalachian College of Pharmacy

Menu
  • Online Application
  • Prospective Students
  • LOGIN
    • Applicant
    • Student
    • Alumni
    • CE Registration
    • Faculty
    • Administration
    • Employer
    • Sponsor
  • Programs
  • COURSES
    • Courses By Semester
    • Course Information

Therapeutic Genome Editing (PHA 4026)

(05/03/2021-07/30/2021)

Course Memo

New therapies that employ genome editing tools are being developed for a broad range of diseases that include sickle-cell disease, beta-thalassemia, Duchenne muscular dystrophy and others. The effectiveness of these genome-based therapies is evident from the case of a patient with sickle-cell disease who underwent treatment that employed genome editing, resulting in remarkable remission from the disease. Encouraged by this success, genome editing technologies are being developed for a large number of diseases, and some of which are already in Phase I/II trials. Some of the diseases are viral infections (hepatitis/HPV), cardiovascular disease, cystic fibrosis, metabolic disorders, defects of the immune system, hemophilia, muscular dystrophy, and development of T cell-based anticancer immunotherapies, all of which are familiar to a PharmD student.
Return
Powered By: Jenzabar company logo
Version 2024
 
  • Administration
  • Alumni
  • Applicant
  • Bookstore
  • Calendars
  • CE Registration
  • Course Information
  • Courses By Semester
  • Employer
  • Faculty
  • Online Application
  • Programs
  • Prospective Students
  • Sponsor
  • Standard Fees
  • Student
SONIS University Campus
DeSelect All
Select All